Use of the Bone Substitute SintLife® in Vertebral Arthrodesis Procedures. A Pilot Study.
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 16
- 试验地点
- 2
- 主要终点
- Spinal fusion
研究概览
简要总结
This pilot study is to evaluate the potential effectiveness of bone substitute SintLife within the spinal surgery in spinal stabilization applications for degenerative diseases.
In particular, the investigators propose to evaluate:
- the ability of bone regeneration/ fusion, defined as the presence of trabecular bone continuous bridge and absence of radiolucent lines, verified by diagnostic imaging in accordance with the Brantigan scale;
- the patient's state of health, evaluated through the comparison of the functional-symptom pattern between the pre- and post-operative phases, verified by Oswestry Disability Index (ODI), Visual Analogue Scale (VAS) and EuroQol (EQ-5D);
- the safety of the medical device, evaluated through the impact of any adverse events, complications, unexpected reactions, accidents.
STUDY DESIGN This collection of clinical data is set up as pilot study post-marketing. In the study will be included all consecutive patients who require spinal fusion surgery, in accordance with the inclusion and exclusion criteria after signing the informed consent. Patients will be treated and followed postoperatively according to the normal clinical, surgical and therapeutic practice, in place at the Rizzoli Orthopaedic Institute of Bologna.
The total duration of data collection is 36 months:
- the stage of patient enrollment is 18 months from the date of approval of the study by the Ethics Committee of the center;
- the phase of post-operative monitoring is 18 months, with planned at 6, 12 and 18 months follow-up (± 15 days before scheduled date).
详细描述
- INTRODUCTION AND RATIONALE The vertebral arthrodesis is one of the surgical procedures most used for the treatment of deformities, trauma and degenerative diseases with instability of the spine (Rajaee et al., 2012; Yoshihara and Yoneoka, 2015).
Using bone grafts and tools, such as metal rods and screws, this procedure creates a fusion between two or more adjacent vertebrae, in order to stabilize the spine.
The success of fusion, intended as the neo-formation of trabecular bone radiographically detectable, may depend on the characteristics of the bone graft used and its properties as well as the surgical technique used. In the absence of autologous bone the biological process that leads to bone regeneration is characterized by three critical elements: the osteogenic potential, the osteoinductive factors, the osteoconductive scaffold. The ideal bone substitute possesses all three of these properties, combined with excellent compatibility and biological safety (Ludwig et al., 2000; Park et al., 2013).
The local autologous bone harvested from the iliac crest has been and is still considered the "gold standard" in the treatment of spinal fusion. However, contraindications and potential complications associated with the use of autologous bone are well known (Dimar et al., 2009; Gruskay et al., 2014; Kim et al., 2009; Miyazaki et al., 2009). In order to overcome these limitations, several alternatives have been developed, clinically tested and are today available on the market: growth factors (BMPs) (Carragee et al., 2011; Kannan et al., 2015), allogenic bone or heterologous ( Gupta et al., 2015; Park et al., 2013), demineralized bone matrix (DBM) and synthetic ceramic materials to name a few (Abdullah et al., 2011; Fischer et al., 2013; Hsu et al., 2012) . Despite all of these materials have been extensively studied (Abdullah et al., 2011; Alsaleh et al., 2012; Hsu et al., 2012; Miyazaki et al., 2009) the available data are often uneven in quality, type of study, assessments performed and conclusions reached (Hsu et al., 2012; Kannan et al., 2015; Miyazaki et al., 2009).
The ceramic bone substitutes of synthetic origin (Nickoli and Hsu, 2014), such as collagen, tricalcium phosphate (TCP) (Dai and Jiang, 2008), calcium phosphate (CaP), calcium sulphate (CaS) and hydroxyapatite (HA), have been designed and developed as osteoconductive scaffolds with characteristics and properties very similar to those of human bone, able to support the regeneration and bone remodeling, and go into slow resorption (Alsaleh et al. , 2012; Gao et al., 2014; Hsu et al., 2012; Kaiser et al., 2014; Kho and Chen, 2008; Korovessis et al., 2005; Lee et al., 2009; Zhou and Lee, 2011) .
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who have provided consent to the processing of personal data;
- •Patients over the age of 18;
- •Patients who require posterolateral fusion of lumbosacral tract (L1- S1);
- •Patients suffering from traumatic and degenerative diseases of the spine, such as lumbar stenosis, spondylolysis and spondylolisthesis, degenerative disc disease;
- •Patients who agree to participate in the program of visits required by the Protocol.
排除标准
- •Patients affected by:
- •systemic or localized infection
- •inflammatory or autoimmune disease
- •hypercalcemia
- •coagulation disorders
- •metabolic disorders
- •insulin dependent diabetes
- •alterations or complications of thyroid function
- •allergy to calcium phosphate
- •declared allergies to medications and / or medical device
- •tumor diseases and / or infectious diseases of the spine
- •active neoplasia
- •Patients who abuse of alcohol or drugs
- •Patients in the alleged pregnancy or confirmed
- •Patients on medication that causes abnormal bone regeneration (eg chemotherapy)
- •Already operated patients (revision surgery)
结局指标
主要结局
Spinal fusion
时间窗: 18 months
Brantigan fusion score to evaluate 5 levels of fusion
次要结局
- Adverse events(18 months)
- Functional activity assessed by ODI (Oswestry Disability Index)(Change from baseline at 6, 12, 18 months)
- Back pain assessed by VAS (Visual Analog Scale)(Change from baseline at 6, 12, 18 months)
- Quality of life assessed by EQ-5D (Euro-QoL5D)(Change from baseline at 6, 12, 18 months)
